Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire rejects $63bn takeover proposal from Takeda
The rare disease drug maker revealed that the Japanese pharma company made three offers recently. Takeda’s latest offer came on 13 April, which was £46.50 per each share
The rare disease drug maker revealed that the Japanese pharma company made three offers recently. Takeda’s latest offer came on 13 April, which was £46.50 per each share
The company has raised the funding from new and existing investors at a pre-money valuation of $2bn in the financing round of the AI pharmaceutical sector. From 2013, BenevolentAI
The German pharma major, which has been looking at various options for the consumer health business since last September, will use the sale proceeds mainly to reduce its
Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is said to be a prophylactic (preventative) treatment that can be administered by an injection of a
Sanofi, which had fully acquired Zentiva in a deal worth about €1.8bn in 2009, is looking to sell it after considering the European generics business to be non-core.
The immuno-oncology combination Opdivo (10mg/mL) and Yervoy (5mg/mL) has been indicated to be intravenously injected in patients with intermediate or poor-risk, advanced RCC, who were previously untreated for
Under the deal, Servier will acquire oncology treatment Oncaspar (pegaspargase), as well as ex-US rights of Onivyde (irinotecan pegylated liposomal formulation). Oncaspar is a component of multi-agent treatment
The findings come from a phase 3 trial called FLAURA which assessed the efficacy and safety of Tagrisso 80mg, administered orally daily at 80mg in comparison with 150mg
As per the terms of the all-cash deal, US-based Alexion via a subsidiary will pay SEK232 ($27.84) for each share of Wilson Therapeutics. The Swedish company is developing
Pfizer said that the committee has asked it to stop the trial, dubbed Atlas, at a planned interim analysis after finding it to be futile. The recommendation had